Local mineralocorticoid receptor activation and the role of rac1 in obesity-related diabetic kidney disease

Nephron - Experimental Nephrology

Volumn 126, Issue 1, 2014, Pages 16-24

  Yoshida, Shigetaka ^a   Ishizawa, Kenichi ^a   Ayuzawa, Nobuhiro ^a   Ueda, Kohei ^a   Takeuchi, Maki ^a   Kawarazaki, Wakako ^b   Fujita, Toshiro ^b   Nagase, Miki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Diabetic nephropathy; Inflammatory cytokines; Mineralocorticoid receptor; Obesity; Rac1

Indexed keywords

ALDOSTERONE; EHT 1864; GLUCOSE; GLUTATHIONE TRANSFERASE; HYDROLASE INHIBITOR; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; RAC1 PROTEIN; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CCL2 PROTEIN, MOUSE; PYRONE DERIVATIVE; QUINOLINE DERIVATIVE; MANNITOL; PROTEIN INHIBITOR;

ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOLOGY; IN VIVO STUDY; KIDNEY HYPERTROPHY; KIDNEY MASS; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; WESTERN BLOTTING; ALBUMINURIA; ANIMAL; C57BL MOUSE; CELL LINE; COMPLICATION; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY; METABOLISM; ORGAN SIZE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; GLOMERULOPATHY; GLUCOSE INTAKE; IN VITRO STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS;

ALBUMINURIA; ANIMALS; BLOTTING, WESTERN; CELL LINE; CHEMOKINE CCL2; DIABETIC NEPHROPATHIES; GLUCOSE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MESANGIAL CELLS; MICE; MICE, INBRED C57BL; OBESITY; ORGAN SIZE; PYRONES; QUINOLINES; RAC1 GTP-BINDING PROTEIN; RECEPTORS, MINERALOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84895577445     PISSN: None     EISSN: 16602129     Source Type: Journal    
DOI: 10.1159/000358758     Document Type: Article

References (35)

1. Coresh J, Selvin E, Stevens L, Manzi J, Kusek JW, Eggers P, et al: Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047. (Pubitemid 350074801)
2. Finucane MM, Stevens G, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al: National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377: 557-567.
3. Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM: Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002; 324: 127-137.
4. De Zeeuw D, Raz I: Albuminuria: a great risk marker, but an underestimated target in diabetes. Diabetes Care 2008; 31(suppl 2):S190-S193.
5. Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, et al: Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 2006; 147: 5363-5373. (Pubitemid 44790591)
6. Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T: Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007; 50: 877-883. (Pubitemid 350287529)
7. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T: Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007; 49: 355-364. (Pubitemid 46143013)
8. Shavit L, Lifschitz MD, Epstein M: Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int 2012; 81: 955-968.
9. Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH, et al: Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 2007; 92: 4472-4475. (Pubitemid 350074772)
10. Kawarazaki H, Ando K, Nagae A, Fujita M, Matsui H, Fujita T: Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats. Nephrol Dial Transplant 2010; 25: 2879-2889.
11. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, et al: Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006; 17: 3438-3446. (Pubitemid 44865286)
12. Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, et al: Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004; 93: 990-996. (Pubitemid 38479452)
13. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al: Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008; 14: 1370-1376.
14. Gee HY, Saisawat P, Ashraf S, Hurd TW, Vega-Warner V, Fang H, et al: ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. J Clin Invest 2013; 123: 3243-3253.
15. Nagase M, Ayuzawa N, Kawarazaki W, Ishizawa K, Ueda K, Yoshida S, et al: Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1. Hypertension 2012; 59: 500-506.
16. Lin CL, Wang JY, Ko JY, Surendran K, Huang YT, Kuo YH, et al: Superoxide destabilization of beta-catenin augments apoptosis of highglucose-stressed mesangial cells. Endocrinology 2008; 149: 2934-2942. (Pubitemid 351724526)
17. Shen E, Li Y, Li Y, Shan L, Zhu H, Feng Q, et al: Rac1 is required for cardiomyocyte apoptosis during hyperglycemia. Diabetes 2009; 58: 2386-2395.
18. Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, et al: Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant 2011; 26: 2475-2484.
19. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, et al: Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 1994; 371: 799-802. (Pubitemid 24333868)
20. Ito T, Tanimoto M, Yamada K, Kaneko S, Matsumoto M, Obayashi K, et al: Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology 2006; 11: 29-35.
21. Yoshida S, Nagase M, Shibata S, Fujita T: Podocyte injury induced by albumin overload in vivo and in vitro: involvement of TGF-beta and p38 MAPK. Nephron Exp Nephrol 2008; 108:e57-e68. (Pubitemid 351592585)
22. Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S, et al: Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest 2011; 121: 3233-3243.
23. Kawarazaki W, Nagase M, Yoshida S, Takeuchi M, Ishizawa K, Ayuzawa N, et al: Angiotensin II-and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J Am Soc Nephrol 2012; 23: 997-1007.
24. Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyren O: Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006; 17: 1695-1702. (Pubitemid 43794672)
25. Lee SH, Yoo TH, Nam BY, Kim DK, Li JJ, Jung DS, et al: Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol 2009; 297:F1381-F1390.
26. Kowluru A, Veluthakal R: Rho guanosine diphosphate-dissociation inhibitor plays a negative modulatory role in glucose-stimulated insulin secretion. Diabetes 2005; 54: 3523-3529. (Pubitemid 43334345)
27. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH: Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006; 69: 73-80. (Pubitemid 43117741)
28. Gilbert KC, Brown NJ: Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes 2010; 17: 199-204.
29. Funder JW: Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol Cell Endocrinol 2004; 217: 263-269. (Pubitemid 38596652)
30. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee M-H, et al: Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006; 17: 1362-1372. (Pubitemid 43673416)
31. Min D, Lyons JG, Bonner J, Twigg SM, Yue DK, McLennan SV: Mesangial cell-derived factors alter monocyte activation and function through inflammatory pathways: possible pathogenic role in diabetic nephropathy. Am J Physiol Renal Physiol 2009; 297:F1229-F1237.
32. Takebayashi K, Matsumoto S, Aso Y, Inukai T: Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006; 91: 2214-2217. (Pubitemid 43855008)
33. Terada Y, Kuwana H, Kobayashi T, Okado T, Suzuki N, Yoshimoto T, et al: Aldosteronestimulated SGK1 activity mediates profibrotic signaling in the mesangium. J Am Soc Nephrol 2008; 19: 298-309. (Pubitemid 351240652)
34. Young MJ: Cardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab 2001; 86: 5121-5126. (Pubitemid 33070224)
35. Nagase M, Fujita T: Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol 2013; 9: 86-98.